Best quality Fast delivery Setmelanotide CAS 1294000-61-5

(4R)-4-(2-chloro-2,2-difluoroethyl)-1-{[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl}pyrrolidin-2-one

1294000-61-5

C14H14ClF5N4O2S

432.045

Polypeptide

87.97

3.4641

83 °C

MC4R (melanocortin-4 receptor) agonist (8-amino-acid cyclic peptide)

FDA-approved (Imcivree 2020) — orphan drug for genetic obesity

A first-in-class, 8-amino-acid cyclic peptide (Ac-Arg-cyclo[Cys-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2) that acts as a selective MC4R agonist. MC4R is a key regulator of hunger, satiety, and energy expenditure in the hypothalamus. Setmelanotide restores melanocortin signaling in patients with genetic defects in the leptin-melanocortin pathway, producing significant weight loss without cardiovascular side effects.

2.1 nM

0.27 nM

DrugBank: DB11700; ChemicalBook: CAS 920014-72-8; target validation: Chen C, et al.

NCT03242581; NCT04234042; NCT05682607

Imcivree (approved 2020-11-25)

DB11700

PubChem

FDA: Imcivree (NDA 213793); NEJM: Clément K, et al. (2020) — Setmelanotide for POMC deficiency

Setmelanotide is FDA-approved as a prescription medicine (Imcivree) for rare genetic forms of obesity (POMC/LEPR deficiency, Bardet-Biedl syndrome, Alström syndrome). This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.